[Skip to Navigation]
February 1950

MESANTOIN® IN TREATMENT OF EPILEPSY: A Report on Two Hundred Patients Under Treatment for Periods Ranging from Two Months to Four Years

Author Affiliations


From the Neurological Unit of the Boston City Hospital, and the Department of Neurology of the Harvard Medical School.

Arch NeurPsych. 1950;63(2):235-248. doi:10.1001/archneurpsyc.1950.02310200043005

THE CORRECT evaluation of any new drug comes only through treating large numbers of patients over long periods and then carefully comparing the results with those obtained with older, proved drugs. Such evaluation includes the limitations and dangers of the new drug, as well as its advantages.

Mesantoin® (3-methyl-5,5-phenylethyl hydantoin) appears to be a valuable addition to the small list of drugs which have been proved effective in the treatment of epilepsy; in fact, I have the impression that it is the most effective antiepileptic agent generally available at this time. Many epileptic patients who had failed to respond satisfactorily to previous medication, including phenobarbital and diphenylhydantoin sodium (dilantin-sodium®), did respond remarkably to mesantoin.®

This paper is a report of my experience in treating 200 epileptic patients with mesantoin® for periods ranging from two months to four years. In this entire group, there was an average

Add or change institution